chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm was hot, red, itchy, bumpy, and swollen.; arm was hot, red, itchy, bumpy, and swollen.; arm was hot, red, itchy, bumpy, and swollen/symptoms have lasted for over a week now since he received his vaccine.; His arm of injection became red and hot. symptoms diminished a bit after a few days/they came back a little bit more intense.; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (arm was hot, red, itchy, bumpy, and swollen.), INJECTION SITE PRURITUS (arm was hot, red, itchy, bumpy, and swollen.), INJECTION SITE ERYTHEMA (His arm of injection became red and hot. symptoms diminished a bit after a few days/they came back a little bit more intense.) and INJECTION SITE SWELLING (arm was hot, red, itchy, bumpy, and swollen/symptoms have lasted for over a week now since he received his vaccine.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     Concurrent medical conditions included Back pain (Takes Tylenol (Acetaminophen) occasionally.).    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced INJECTION SITE ERYTHEMA (His arm of injection became red and hot. symptoms diminished a bit after a few days/they came back a little bit more intense.). On 26-Apr-2021, the patient experienced FEELING HOT (arm was hot, red, itchy, bumpy, and swollen.), INJECTION SITE PRURITUS (arm was hot, red, itchy, bumpy, and swollen.) and INJECTION SITE SWELLING (arm was hot, red, itchy, bumpy, and swollen/symptoms have lasted for over a week now since he received his vaccine.). At the time of the report, FEELING HOT (arm was hot, red, itchy, bumpy, and swollen.), INJECTION SITE PRURITUS (arm was hot, red, itchy, bumpy, and swollen.), INJECTION SITE ERYTHEMA (His arm of injection became red and hot. symptoms diminished a bit after a few days/they came back a little bit more intense.) and INJECTION SITE SWELLING (arm was hot, red, itchy, bumpy, and swollen/symptoms have lasted for over a week now since he received his vaccine.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medications included acetaminophen. Concomitant medications were not reported.
Patient had a fever and seizure episode seen at hospital. Dxed febrile seizure 5/6/15 d/c home. Had f/u on 57/15 pt still have a fever 102 but no episode of seizure. Pt playful and physical exam normal.
mom reported site became red & swollen on Friday 9/10/99;By afternoon it was 2x the size-very hot w/large red bump in center;
Patient was here during covid giving hours and requested a shingles vaccine. Vaccinating pharmacist accidently gave him a 3rd dose of Covid vaccine. His first two doses were Moderna in January.
Patient fainted, he was able to get up on his own.  He sat in a chair by the pharmacy for 15 minutes and drank water.  When he felt better he left with a friend.
Narrative: Pt was a 78 YO male with PMH of HTN, HLD, cardiomyopathy, and dementia who was discharged to home hospice care due to his dementia diagnosis.
In the middle of the day, I started getting a sore throat and the next day I developed a runny nose. Rapid COVID-19 test on 3/10 positive. Sought care at urgent care 3/12, LAGEVRIO was prescribed. Started taking that same day. Over the next few days, I saw symptoms diminish. It took about 7 days to feel recovered.
intense nausea; fatigue; chills; headache; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via unspecified route of administration in the left arm on 19Mar2021 at 16:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via unspecified route of administration in the left arm on 23Feb2021 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021, 12-24 hours after shot, the patient experienced fatigue, chills and headache. The next day on 21Mar2021, 36-48 hours after shot, complete improvement was seen followed by relapse of fatigue, chills, and intense nausea on the following day on 22Mar2021 (72 hours after shot). Treatment was not received for the reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the headache was resolved on 21Mar2021 and outcome of fatigue, chills and nausea was unknown at the time of reporting.   No follow-up attempts are needed. No further information is expected.
pt recv vax 16MAY96 & approx 01JUN96 pt devel full-blown chickenpox;
Sudden neck, shoulder, hip stiffness since diagnosed as PMR.  Dr visit Dec 21, 2021.  Start prednisone Dec 22.
It looks like a patient has a cellulitis on the bicep. Patients arm was red and inflamed. It was painful and warm to the touch instructed to take BENADRYL & go to ER. Patient came in 2 hour after vaccine.
Initial unsolicited report received from a nurse on 09 October 2015. This case involves a 34-year-old female patient who was vaccinated with a dose of FLUZONE QIV (batch number: U5310DB, dose, dose in series and site of administration were not reported) intramuscularly on 06 October 2015. The patient's illness at time of vaccination reported as no and pre-existing physician diagnosed allergies, birth defects, medical conditions reported as allergy to house dust and pollen. Concomitant medications were not reported. On 07 October 2015, one day following the vaccination, the patient had experienced body aches, felt like she had a fever (temperature not measured). The patient required ER/doctor visit. Laboratory data and corrective treatment was not reported. The outcome of the event was not reported. List of documents held by sender: none. Follow up information received from a nurse on 22 December 2015. The patient had received 0.5ml dose of vaccine on left deltoid. It was reported that, previously on an unspecified date, the patient had received prenatal vitamins as previous medication. On 11 October 2015, four days after the onset of events, the patient was recovered from the events.
Heart/chest pain. Doesn't seem to relate to activity, occurs multiple times per day but only lasts a minute or so. 3/10 pain
Raised bumps along hairline 10/18 with fatigue, headache, joint pain, stiff neck intermittent fatigue/headache/joint pain/stiff neck/low grade fever through 10/31. 10/31-spiked fever to 102, mouth sores, petechiae on back. Intermittent symptoms continue. Fever up and down, joint pain ongoing, etc. 11/5 chills, fever, sore throat, intermittent chest discomfort with breaths periodically, continued joint pain, neck stiffness, fever, sore throat, etc.
Patient presents with a 2 week declined marked by shortness of breath and fatigue.  He was noted to have melenic stool at the extended care facility.  On admission his hemoglobin was 7.8 and then the repeat hemoglobin after 3 hours came back 6.1 . Patient has a remote history of peptic ulcer disease.  Colonoscopy 6 months ago unremarkable except for diverticulosis and benign polyps.  Patient denies bright red blood per rectum.  Patient is not on anticoagulation.  Patient denies use of NSAID or aspirin products.  Pt found to be COVID +, no hypoxia, afebrile, Chest xray stable airspace disease.  Pt treated for GI bleed and discharged 2/3/22.  Previously vaccinated Moderna 3/23/21, 4/20/21, 8/19/21
Patient states he had a hard time walking and was starting to get a fever but this was kept down due to tylenol
pt began running temp & crying for long periods of time the evening of 13JUL94; mom stated temp would not go down t102 even w/APAP; mom called clinic 15JUL94 & was advised to go to ER; pt legs were not red;swelling was nl;
Initial report received from scientific literature on 12 June 2012. The following is verbatim from the article: "Background: Children are at high risk of acquiring and transmitting influenza infection and are a high priority group for INFLUENZA vaccination. Methods: This was a randomized, observer-blind, multicenter study (NCT00980005). Children were randomized (1:1) to receive either the study vaccine, a thimerosal-free trivalent inactivated INFLUENZA vaccine or an active comparator (control vaccine) and were allotted to 1 of 3 age categories: 3-4, 5-8 and 9-17. The primary objective was to show noninferiority of the study vaccine versus licensed control INFLUENZA vaccine. Results: A total of 2116 children were vaccinated (study vaccine N = 1055, control vaccine N = 1061). The predefined noninferiority criteria and the Center for Biologics Evaluation and Research criteria for clinical benefit were met for all 3 seasonal virus strains in all children and each age strata. The ratios of the adjusted geometric mean titers (control vaccine over study vaccine) ranged from 0.93 to 1.03 for the 3 virus strains whereas the differences in seroconversion rate (control vaccine minus study vaccine) were between 22.42% and -1.60%. Post vaccination geometric mean titers (range: 213.7-414.7 versus 200.2-451.9) and seroconversion rates (range: 59.8-81.1% versus 58.2-78.6%) were comparable for the 2 vaccines. The safety and reactogenicity profiles were similar for both treatment groups in all age strata. Conclusions: Immunologic noninferiority of the study vaccine was demonstrated compared with the control vaccine. Furthermore, the study vaccine had a similar safety profile as the control vaccine in children." A "four-year-old male child" received an injection of dose two of FLUZONE, sanofi pasteur Inc., (lot number, route and site not reported on an unspecified date. On an unspecified date later "during the follow-up phase", he developed "insulin-dependent (Type 1) diabetes mellitus", which the investigator considered related to the vaccination. The patient's outcome was reported as not recovered at the conclusion of the study. Documents held by sender: None.
Pt received Diphtheria Tetanus 0.5 cc/IM on 3/26/08. Pt returned to ED stating "the DT shot gave her an infection. Declined treatment: followed up with Primary physician (3/28/08).
Immediate sever reaction with fever after 2nd dose, musle pain and fatigue continued and strong uncomfortable chest pain developed, fearing cardiac problems, went to ER. No cardiac indications from bloodwork or xrays. Diagnosis was  costochondritis.
It started that evening with the pain in the arm. And it went down hill from there. I have never been in so much pain ever in my life. My hands were freezing cold and it felt like someone was jabbing me with a knife all night long. Because of the stress on my muscles I could barely walk the next day. Starting the evening of the next day my arm and lymph gland were both swollen. I know there?s symptoms that can be uncomfortable but I couldn?t believe how bad and painful it was. I wouldn?t of got it.  Thank you.
Symptoms: generalized puritus Outcomes: monitored for 45 min and given PO Benadryl and resolved
Initial report received from a consumer on 15 November 2011. A male patient (age not reported) received an injection of FLUZONE, sanofi pasteur Inc. lot number U1905AA, on 28 October 2005. The patient had a history of hepatitis C and completed treatment with interferon. The patient had no other vaccines within 4 weeks of the FLUZONE. The next day after receiving the FLUZONE, the patient developed a strange feeling, and then developed rash, tongue swelling, difficulty in walking, hard to concentrate. Three days later the patient received an injection of PNEUMOVAX, manufacturer and lot number not reported. The day after the PNEUMOVAX, the patient's previous reactions of feeling strange and difficulty walking became worse. The patient was unable to move for 4 hours and then after the 4 hours was able to slowly move but had severe pain. The patient had joint pain and the sensation of burning feet. The patient had a diagnosis of neuropathy and has continued to worsen over the years. The outcome was reported as not recovered. Documents held by sender: None.
Sore Left arm for 48 hrs and lynphedema in neck an both ankles. Burning pain in left scapula area.  Recovered from all , except buring pain in Left scapula pain.
Information has been received from a licensed practical nurse concerning a 16 year old female with no pertinent medical history who on 29-JAN-2007 was vaccinated, intramuscularly , into the left deltoid, with a 0.5 ml dose of GARDASIL (lot #"1424K"). There was no concomitant medication. On 08-FEB-2007 the patient developed optic neuritis, blurred vision and double vision and was hospitalized. The patient was discharged from the  hospital on 13-FEB-2007 when her vision returned to normal. At the time of the report, the patient was recovering under the care of a retinoligist. Additional information has been requested. 05/29/07-records received for DOS 2/8-2/11/07-DX blurry vision left eye. Seen by ophtho on day of admission fr optic neuritis vs. pseudotumor cerebri. Acute onset of painless blurry vision left eye and seeing double for one day. No headache.
Information has been received from a health care worker (C.M.A) concerning a patient of unknown age who on 01OCT2012 was vaccinated with rotavirus vaccine, live, oral, pentavalent. The health care worker reported that the patient was administered an expired dose of rotavirus vaccine, live, oral, pentavalent. No adverse effect was reported. Additional information has been requested.
Patient fainted, lost consciousness and seized for 10 secs. Then regained full consciousness with the help of alcohol. BP check was normal, no suspected pregnancy, possible result of anxiety/panic
None. Package insert had expiration date at 12/31/2069, unknown to us, this was not correct. Moderna found with proper storage, the vaccine maintained the activity necessary to protect against the SARS-COV-2 virus at the time of administration. Viability check done by Moderna found vaccine to be viable and effective.
Positive for Covid; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive for Covid) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Feb-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Positive for Covid). At the time of the report, SARS-COV-2 TEST POSITIVE (Positive for Covid) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information was provided.  Very limited information regarding these events has been provided at this time. Further information has been requested.; Sender's Comments: Very limited information regarding these events has been provided at this time. Further information has been requested.
Around 11pm approximately 15 hours or so after the injection, I began with severe arm pain at the sight of injection (could not raise arm), body aches, fatigue, fever, and I ended up fainting. I fainted after trying to sit up, for maybe a few seconds, before coming to. Then proceeded with shaking and cold sweats through the night. Next day is better, but still body aches, fatigue and very small fever of 99.5
Anaphylaxis (raised heart rate, rash, nausea and vomiting, swollen lips and throat) difficulty breathing - anaphylaxis under control  Cause may be a salad Breathing still doesn?t feel normal
Narrative: Patient hospitalized due to COVID infection; acute hypoxic and hypercapneic respiratory failure
Pt recvd 2 doses of Engerix-B & 4 days following 2nd dose devel itchy, papular rash on forearms & both flanks; seen by MD where employed; treated itching w/Penactin;
Vaccine administered on 6/22/2009 Left leg redness left leg pain, fever on 6/23/09. Continued redness left leg on 6/24/09 decreased pain, decreased fever.
Pt recvd Recombivax & Engerix-B (dose 2 & 3) & exp non-response as of 16MAR92; 4th dose of Engerix-G given; titer still neg;
Red rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced RASH ERYTHEMATOUS (Red rash). At the time of the report, RASH ERYTHEMATOUS (Red rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication was reported.    No treatment medications were reported.   This case was linked to MOD-2021-419233, MOD-2021-419298 (Patient Link).
This case was reported by a healthcare professional (nurse practitioner) and described the occurrence of arm pain ("pain on arm that radiates to the shoulder") in a 49-year-old male subject who was vaccinated with ENGERIX B, (GlaxoSmithKline). On 10 February 2012 at 09:15 the subject received 1st dose of ENGERIX B (unknown route, right arm). Less than one week after vaccination with ENGERIX B, the subject experienced arm pain ("pain on arm that radiates to the shoulder"). The subject had had "many" labs and has seen different physicians. No further information was provided. The healthcare professional considered the event was disabling and clinically significant (or requiring intervention). At the time of reporting the event was worse. The healthcare professional considered the event was possibly related to vaccination with ENGERIX B.
Cold chills. Pain in body sick, vomited neon green fatigue, restless felt like had vovid
abnormal uterine bleeding. Greater than 14 days each time. Heavier than normal.
Severe pain at site with redness, warmth and tenderness to touch. Fever 103 degrees F.
Systemic: Pt had a panic attack and felt weak, laid on floor to avoid fainting-Mild, Additional Details: PT has severe vaccine anxiety. Pt always passes out after vaccination from the anxiety and adrenaline. Pt took a valium at some point prior to receiving vaccination at home.
Pt describes pain at injection site as well as tingling/numbness down left arm within 1-2 hours after injection. Had malaise x 10 days causing him to be bedridden during that time. No fever/chills/sweats. Now still with soreness at injection site with numbness and tingling down left arm 2 months later. Slightly improved compared to two weeks ago.
very sore arm for two days; arm is now very itchy; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (very sore arm for two days) and VACCINATION SITE PRURITUS (arm is now very itchy) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (very sore arm for two days) and VACCINATION SITE PRURITUS (arm is now very itchy). At the time of the report, VACCINATION SITE PAIN (very sore arm for two days) had resolved and VACCINATION SITE PRURITUS (arm is now very itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   Reporter did not allow further contact.
This spontaneous report was received from a pharmacist refers to a 20 year old patient of an unknown gender. The patient's relevant medical history, concurrent condition and concomitant medication were not reported. On an unknown date, the patient was erroneously vaccinated with a dose of ZOSTAVAX instead of VARIVAX (lot number/expiry date and dosage not reported). No adverse effects were reported. No Product Quality Complaint (PQC) was involved. Additional information has been requested.
Patient came to pharmacy and stated that he had received the influenza vaccine 10/3/15 and was still having arm pain and decreased range of motion in shoulder.
Pt received Tdap on 6/24/2011. On 6/27/2011 he presented with c/o fever, soreness in joints & was using a cane. Sent to Urgent Care for evaluation.
This spontaneous report as received from a medical assistant and refers to a "couple of patients" of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 12-SEP-2016, the patient's were vaccinated with improperly stored ZOSTAVAX 19400 Plaque Forming Unit (dose and route not reported) from lot # L046900 with expiry date of 23-FEB-2017, lot # L039095 with expiry date of 15-JAN-2017. The vaccines were exposed to a temperature of 11.87 Fahrenheit for a time frame of 1 to 5 minutes. Digital data logger was involved. No adverse events were reported. No product quality complaint was involved. Additional information has been requested.
This spontaneous report as received from a nurse practitioner via a company representative refers to a patient of unknown age and gender. On 14-JUN-2013 the patient was vaccinated with a dose of VARIVAX (Merck) (lot #, dose, frequency and route unspecified) when she was suppose to receive ZOSTAVAX. No adverse symptoms reported. Additional information has been requested.
Information has been received from a 59 years old female consumer referring to herself. As medical history the patient reported an unknown disability. On 14-APR-2015 the patient was vaccinated with a dose of ZOSTAVAX injection (unspecified dose and route). Concomitant therapies included Lisinopril (manufacturer unknown) and NAPROXEN. The patient stated she did not have any adverse reactions at the moment of vaccination, but reported that recently on 25-JUN-2015, she experienced itching, redness and pain on her right side and around her neck. The patient stated the symptoms lasted about 5-6 minutes and then subsided; however she still has some blistering, so the outcome of the events was reported as recovering. Additional information has been requested.